Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Low-Intensity Chemotherapy and Venetoclax in Treating Patients with Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory T Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03808610
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT03799913
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma
- Conditions
- Non-hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Soonchunhyang University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT03794167
- Locations
- 🇰🇷
Jong-Ho Won, Seoul, Korea, Republic of
Multicenter Registry of Pediatric Lupus Nephritis in China
- Conditions
- Lupus NephritisChildrenSteroidImmunosuppressive Treatment
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Xiqiang Dang
- Target Recruit Count
- 1200
- Registration Number
- NCT03791827
- Locations
- 🇨🇳
The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- GanglioneuroblastomaHigh Risk Neuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: DexrazoxaneBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideRadiation: External Beam Radiation TherapyDrug: IsotretinoinDrug: MelphalanBiological: SargramostimDrug: ThiotepaDrug: TopotecanDrug: Vincristine
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- Conditions
- Acute Biphenotypic LeukemiaAcute LeukemiaAcute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Undifferentiated LeukemiaAllogeneic Hematopoietic Stem Cell Transplantation RecipientBlastic Plasmacytoid Dendritic Cell NeoplasmBlasts Under 25 Percent of Bone Marrow Nucleated CellsBlasts Under 5 Percent of Bone Marrow Nucleated CellsMixed Phenotype Acute Leukemia
- Interventions
- Radiation: Total-Body IrradiationDrug: ThiotepaDrug: FludarabineDrug: CyclophosphamideDrug: BusulfanDrug: TacrolimusProcedure: Allogeneic Bone Marrow TransplantationDrug: MethotrexateProcedure: Naive T Cell-Depleted Hematopoietic Stem Cell TransplantationProcedure: EchocardiographyProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT03779854
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
- Conditions
- Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
- Interventions
- Drug: RituximabDrug: FludarabineDrug: CyclophosphamideBiological: MG4101(allogeneic Natural Killer cell)Drug: Interleukin-2
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- GC Cell Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03778619
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National Univ. Hospital, Seoul, Korea, Republic of
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
- Conditions
- Metastatic MelanomaSquamous Cell Skin Carcinoma
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Turnstone Biologics, Corp.
- Registration Number
- NCT03773744
Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease
- Conditions
- Interstitial Lung DiseaseAntisynthetase Syndrome (ASS)
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 76
- Registration Number
- NCT03770663
- Locations
- 🇫🇷
Hôpital Universitaire Pitié Salpêtrière, Paris, France
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
- Conditions
- B-cell Lymphoma
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 42
- Registration Number
- NCT03761056
- Locations
- 🇺🇸
Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷Hopital Saint Louis, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.